Grifols (NASDAQ:GRFS) Trading Down 3.7% - Time to Sell?

Shares of Grifols, S.A. (NASDAQ:GRFS - Get Free Report) fell 3.7% during trading on Friday . The company traded as low as $7.16 and last traded at $7.20. 616,128 shares were traded during trading, a decline of 10% from the average session volume of 683,670 shares. The stock had previously closed at $7.47.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a report on Tuesday, October 29th.

Grifols Stock Performance

The stock's 50-day moving average is $7.66 and its 200-day moving average is $8.19. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The stock has a market cap of $5.05 billion, a price-to-earnings ratio of 6.13 and a beta of 0.41.

Institutional Trading of Grifols

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in shares of Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock worth $30,000 after buying an additional 1,135 shares during the period. R Squared Ltd purchased a new position in Grifols in the 4th quarter worth approximately $28,000. Signaturefd LLC grew its position in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 2,153 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 4,970 shares during the period. Finally, HighTower Advisors LLC raised its stake in shares of Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 1,546 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.